ArticleNature immunology2016
Foxp3 and Toll-like receptor signaling balance T
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 378 papers.
0numbers the graph read from it
0cells of the map it votes in
378citing papers in PubMed
20.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
378 citing papers in PubMed, 509 citations in OpenAlex.
- The anti-inflammatory potential of nicotinamide (vitamin B3) in JIA: modulating Treg numbers and function with nicotinamide.Arthritis research & therapy · 2026Trial
- Inducible cAMP Early Repressor Limits Glycolytic Programming in Regulatory T Cells and Supports Control of Inflammatory Colitis.European journal of immunology · 2026Article
- Regulatory T cell induction strategies and applications in the treatment of immune and non-immune diseases.Signal transduction and targeted therapy · 2026Review
- Lactylation Modification and Esophageal Cancer: Research Progress From Hypoxia-Induced Metabolic Reprogramming to Immune Escape.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Mitochondrial Metabolic Reprogramming and Skin Immune Homeostasis: From Basic Mechanisms to Therapeutic Perspectives.Immune network · 2026Review
- Review
- The Glucose Transporter GLUT3 Controls Regulatory T Cell Function.European journal of immunology · 2026Article
- Nrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma.Nature communications · 2026Article
- FAS-controlled T cells drive lymphoproliferation through glycolysis without effector differentiation.Journal of human immunity · 2026Article
- Regulatory T cells as a potential treatment for autoimmune inflammatory rheumatic and musculoskeletal diseases.Clinical rheumatology · 2026Review
- Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026Review
- Glucose metabolic reprogramming as a driver of immunosuppression in the tumour microenvironment.Clinical and translational medicine · 2026Review
- Targeting tumor-infiltrating regulatory T cells based on immunometabolism.Cancer biology & medicine · 2026Review
- CD4Cancer biology & medicine · 2026Review
- SUMOylation is destined for regulatory T cell-related immune dysregulation.Cell death discovery · 2026Review
- PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease.Nature reviews. Rheumatology · 2026Review
- Targeting DAP5 Disrupts Alternate Mode of Translational Initiation in Tregs and Potentiates Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- LAG-3Immunology · 2026Article
- Dysregulated immunometabolism in gut inflammation.Acta biochimica et biophysica Sinica · 2026Review
- T cell-intrinsic PRR signaling in immunity and pathology.Acta biochimica et biophysica Sinica · 2026Review
318 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 6 institutions in 1 country.
Valerie A GerrietsDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, USA.
Rigel J KishtonDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, USA.
Marc O JohnsonDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, USA.
Sivan CohenDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, USA.
Peter J SiskaDepartment of Pathology, Microbiology, and Immunology, Vanderbilt Center for Immunobiology, Vanderbilt University, Nashville, Tennessee, USA.
Amanda G NicholsDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, USA.
Marc O WarmoesCenter for Environmental and Systems Biochemistry, Department of Toxicology and Cancer Biology and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Aguirre A de CubasDepartment of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Nancie J MacIverDivision of Pediatric Endocrinology and Diabetes, Duke University, Durham, North Carolina, USA.
Jason W LocasaleDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, USA.ORCID http://orcid.org/0000-0002-7766-3502
Laurence A TurkaMassachusetts General Hospital, Center for Transplantation Sciences, Boston, Massachusetts, USA.
Andrew D WellsDepartment of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jeffrey C RathmellDepartment of Pathology, Microbiology, and Immunology, Vanderbilt Center for Immunobiology, Vanderbilt University, Nashville, Tennessee, USA.
Duke University · USVanderbilt University · USChildren's Hospital of Philadelphia · USMassachusetts General Hospital · USUniversity of Kentucky · USVanderbilt University Medical Center · US
Funding
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5MXENOGENIC TOLERANCE IN MICEP01HL018646 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ALLAN, JAMES S. · 1985 to 2019
$37.5MBIOCHEMICAL &CHEMICAL TRAINING FOR CANCER RESEARCHT32CA009582 · NCI · VANDERBILT UNIVERSITY · PI David K Cortez · 1987 to 2026
$8.8MTransgenic and mutant animalP01AI073489 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GREENE, MARK I · 2008 to 2012
$7.1MExploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory diseaseR01DK105550 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey C Rathmell · 2015 to 2026
$4.7MRegulation of Foxp3 FunctionR01AI070807 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · PI WELLS, ANDREW D · 2008 to 2012
$2.0MT cell metabolism as a determinant of differentiation in allergic asthmaR01HL108006 · NHLBI · VANDERBILT UNIVERSITY · PI RATHMELL, JEFFREY C. · 2011 to 2014
$1.5MUnderstanding metabolic flux and the control of mammalian cell growthR00CA168997 · NCI · DUKE UNIVERSITY · PI LOCASALE, JASON W. · 2013 to 2015
$695kTargeting aerobic glycolysis in T-ALLF31CA183529 · NCI · DUKE UNIVERSITY · PI KISHTON, RIGEL JOSEPH · 2014 to 2016
$84kNCI NIH HHS F31 CA183529NCI NIH HHS R00 CA168997NCI NIH HHS T32 CA009582NHLBI NIH HHS P01 HL018646NHLBI NIH HHS R01 HL108006NIAID NIH HHS P01 AI056299NIAID NIH HHS P01 AI073489NIAID NIH HHS R01 AI070807NIDDK NIH HHS R01 DK105550
Abstract
CD4
Indexed as
AnimalsCell DifferentiationCell ProliferationCells, CulturedForkhead Transcription FactorsGlucose Transporter Type 1GlycolysisImmune ToleranceMechanistic Target of Rapamycin Complex 1MetabolismMiceMice, Inbred C57BLMice, TransgenicMultiprotein ComplexesProto-Oncogene Proteins c-aktSignal TransductionForkhead Transcription FactorsFoxp3 protein, mouseGlucose Transporter Type 1Mechanistic Target of Rapamycin Complex 1Multiprotein ComplexesProto-Oncogene Proteins c-aktSlc2a1 protein, mouseToll-Like ReceptorsTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.